Morning Overview on MSN

Magic mushroom therapy just jumped closer to FDA approval

The U.S. Food and Drug Administration issued its first formal guidance on how to design and run clinical trials for ...

Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise

See what Compass Pathways’ Phase 3 COMP360 TRD data showed, why the stock jumped, and how a discounted offering reshapes the near-term setup.
The Wall Street Transcript

Psilocybin Magic Mushrooms are Now a Publicly Traded Investment Vehicle: COMPASS Pathways (NASDAQ:CMPS)

George Goldsmith is the Chairman, CEO and Co‑Founder of COMPASS Pathways (NASDAQ:CMPS). Mr. Goldsmith’s early training and experience was a multi-disciplinary blending of cognitive psychology, ...
Business Wire

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

“The positive top-line results at week 6 from the COMP005 trial underscore the innovative potential of psilocybin treatment in mental health care for which Compass Pathways continues to pave the way,” ...
MoneyWeek

COMPASS Pathways: the biotech aiming to beat depression with magic mushrooms

Rarely do investors have the opportunity to invest in a pharmaceutical company doing clinical trials where the drug awaiting regulatory approval has been in use for decades. The US government has ...